Cardiac myosin inhibitors
- Reduce excessive sarcomere contractility
- Obstructive HCM is the key use
- Can improve obstruction + symptoms
- Excess effect → systolic dysfunction/HF
- Echo-guided dosing/monitoring is essential
- CYP interactions are important for mavacamten
Class at a glance
- Reduce excessive sarcomere contractility
Pharmacology
- CYP interactions are important for mavacamten
Clinical role
- Obstructive HCM is the key use
- Can improve obstruction + symptoms
Safety / monitoring
- Excess effect → systolic dysfunction/HF
- Echo-guided dosing/monitoring is essential
Self-check
- What do Cardiac myosin inhibitors primarily reduce?
excessive sarcomere contractility.
Drugs in this class (2)
All drug classes · Open the interactive console ↗
